Samsung Bioepis and Sandoz announced a global agreement on March 18, 2026, to develop and commercialize up to five next-generation biosimilars, including SB36 referencing Entyvio (vedolizumab). Samsung Bioepis handles development, regulatory registration, and manufacturing; Sandoz manages commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and South Korea. SB36 is in pre-clinical development for Crohn's disease, ulcerative colitis, and pouchitis. This builds on prior collaborations like PYZCHIVA (ustekinumab) launched in Europe (July 2024) and US (February 2025), and EPYSQLI for Middle East and Africa (December 2025). The deal expands Sandoz's biosimilar pipeline to up to 32 assets and focuses on immunology and oncology. Sources:
- Get link
- X
- Other Apps